新药 | 靶点 | 适应症 | 研发企业 | 状态 | 2018年销售额 |
nivolumab | anti-PD1单抗 | 黑素瘤,肺癌 | Bristol-Myers Squibb | Phase III | 39.22 |
MK-3475 | anti-PD1单抗 | 黑素瘤 | Merck | Phase III | 16.46 |
apremilast | PDE4抑制剂 | 类风湿性关节炎 | Celgene | Filed | 12.19 |
serelaxin | 重组人relaxin-2 | 急性心衰 | Novartis | Filed | 9.03 |
dulaglutide | 长效GLP-1类似物 | II型糖尿病 | Eli Lilly | Filed | 8.35 |
empagliflozin | SGLT2抑制剂 | II型糖尿病 | Boehringer Ingelheim | Filed | 7.69 |
Afrezza | 吸入型胰岛素 | I/II型糖尿病 | MannKind | Filed | 7.25 |
Eloctate | 长效重组因子VIII | A型血友病 | Biogen Idec | Filed | 6.92 |
ramucirumab | anti-VEGFR2单抗 | 胃癌 | Eli Lilly | Filed | 6.84 |
LY2963016 | 甘精胰岛素 | I/II型糖尿病 | Eli Lilly | Filed | 6.49 |
secukinumab | anti-IL-17单抗 | 银屑病 | Novartis | Filed | 5.72 |
idelalisib | PI3K抑制剂 | 慢性淋巴细胞白血病 | Gilead Sciences | Filed | 5.28 |
V503 | HPV疫苗 | HPV相关肿瘤 | Merck | Phase III | 5.21 |
Plegridy | PEG-干扰素β-1a | 多发性硬化症 | Biogen Idec | Filed | 5.04 |
CXA-201 | ceftolozane+tazobactam | 细菌感染 | Cubist Pharma | Phase III | 4.73 |
ENB-0040 | asfotase alfa | 磷酸酶过少症 | Alexion Pharma | Phase III | 4.67 |
Contrave | 安非他酮+纳曲酮 | 减肥 | Takeda | Filed | 3.95 |
Zerenex | 柠檬酸铁 | 高磷血症 | Keryx Biopharma | Filed | 3.92 |
tavaborole | leucyl-tRNA合成酶抑制剂 | 甲癣 | Anacor Pharma | Filed | 3.81 |
欢迎光临 药群论坛 (http://yaoqun.net/) | Powered by Discuz! X3.2 |